345 related articles for article (PubMed ID: 9745421)
21. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group.
Buysschaert M; Bobbioni E; Starkie M; Frith L
Diabet Med; 1999 Feb; 16(2):147-53. PubMed ID: 10229309
[TBL] [Abstract][Full Text] [Related]
22. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
[TBL] [Abstract][Full Text] [Related]
23. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
Antonucci T; Whitcomb R; McLain R; Lockwood D; Norris RM
Diabetes Care; 1997 Feb; 20(2):188-93. PubMed ID: 9118772
[TBL] [Abstract][Full Text] [Related]
24. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
25. The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.
Schuster D; Gaillard T; Rhinesmith S; Habash D; Osei K
Metabolism; 2003 Sep; 52(9):1211-7. PubMed ID: 14506629
[TBL] [Abstract][Full Text] [Related]
26. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C
Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395
[TBL] [Abstract][Full Text] [Related]
27. Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent.
Osei K; Falko JM
Am J Med Sci; 1985 Apr; 289(4):148-53. PubMed ID: 3920907
[TBL] [Abstract][Full Text] [Related]
28. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
[TBL] [Abstract][Full Text] [Related]
29. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.
Ghazzi MN; Perez JE; Antonucci TK; Driscoll JH; Huang SM; Faja BW; Whitcomb RW
Diabetes; 1997 Mar; 46(3):433-9. PubMed ID: 9032099
[TBL] [Abstract][Full Text] [Related]
30. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
[TBL] [Abstract][Full Text] [Related]
31. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Ohmura E; Hosaka D; Imai Y; Kawazu S
Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
[No Abstract] [Full Text] [Related]
32. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
Katsuki A; Sumida Y; Murata K; Furuta M; Araki-Sasaki R; Tsuchihashi K; Hori Y; Yano Y; Gabazza EC; Adachi Y
Diabetes Obes Metab; 2000 Jun; 2(3):189-91. PubMed ID: 11220554
[TBL] [Abstract][Full Text] [Related]
33. Effect of troglitazone on endothelial function in type 2 diabetic patients.
Takase H; Hakamata M; Toriyama T; Hayashi K; Gotoa T; Sato K; Ueda R; Dohi Y
Arzneimittelforschung; 2002; 52(1):34-8. PubMed ID: 11838272
[TBL] [Abstract][Full Text] [Related]
34. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
Maruyama S; Yanagisawa K; Kanamuro R; Teno S; Iwamoto Y
Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
[TBL] [Abstract][Full Text] [Related]
35. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
36. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
37. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.
Iwamoto Y; Kuzuya T; Matsuda A; Awata T; Kumakura S; Inooka G; Shiraishi I
Diabetes Care; 1991 Nov; 14(11):1083-6. PubMed ID: 1797492
[TBL] [Abstract][Full Text] [Related]
38. Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects.
Foot EA; Eastmond R
Diabetes Res Clin Pract; 1997 Oct; 38(1):41-51. PubMed ID: 9347245
[TBL] [Abstract][Full Text] [Related]
39. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
Phillips LS; Grunberger G; Miller E; Patwardhan R; Rappaport EB; Salzman A;
Diabetes Care; 2001 Feb; 24(2):308-15. PubMed ID: 11213884
[TBL] [Abstract][Full Text] [Related]
40. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.
Mimura K; Umeda F; Hiramatsu S; Taniguchi S; Ono Y; Nakashima N; Kobayashi K; Masakado M; Sako Y; Nawata H
Diabet Med; 1994; 11(7):685-91. PubMed ID: 7955995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
